FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Breathing life into a dying language









The Uchinaaguchi class opened with a "good morning."


"Ukimi soo chii," said the teacher, Chogi Higa.


"Ukimi soo chii," the students repeated.





For student Tokie Koyama, the greeting was a bittersweet echo of her childhood on Okinawa.


"It makes me cry," she told the class. "I miss home."


Famous for its military bases and World War II battlefields, the Japanese island chain of Okinawa is also home to a language as different from Japanese as English is from German. A Japanese speaker in Higa's class would be lost from the get-go — "good morning" in Japanese is "ohayo gozai masu."


These days, the lingua franca of the Okinawan islands is Japanese, not Uchinaaguchi. Higa's students are studying a dying language. But for them, it is a language full of emotional triggers, conjuring up parents who used it so their children wouldn't understand, or grandparents thrilled to hear the younger generation speak a few words in the mother tongue.


The youngest student is in high school; the oldest, an octogenarian. Most are second-, third- or fourth-generation Okinawan Americans, though a few are drawn by an interest in island music and culture. Twice a month, they greet each other with a "Hai sai" and wrestle with such phrases as "Uganjuu-yamiseemi" — "How are you?" — that are tongue twisters for English and Japanese speakers alike. Higa's Gardena classroom is perhaps the only place in the continental United States to learn Uchinaaguchi.


"Being Okinawan is so different from being just pure Japanese, though of course, I'm American first," said Joan Oshiro, 68. Oshiro is fluent in Japanese but heard only snippets of Uchinaaguchi growing up in Hawaii. "Spanish may be more practical, but this is a way to learn a little bit about yourself and pass it on to your children."


Higa remembers wearing a wooden plaque labeled "dialect user" as punishment for speaking Uchinaaguchi at school — a common memory for older Okinawans. In the postwar years, mainstream radio and television programs in Japanese saturated the airwaves. Bombarded by these influences, Okinawans didn't pass their language to the next generation. Japanese became the language of the home, the school and the workplace.


In the islands, elderly Okinawans still shoot the breeze with one another in Uchinaaguchi. The folk music wafting out of open pub doors is still sung in the old tongue. But the language needs help to survive. Revival efforts in recent years have included speech contests and radio programs. Thousands of miles away in Southern California, Higa is doing his part.


For many years, he hosted an Uchinaaguchi program on a Los Angeles Japanese-language radio station. He has been teaching the Uchinaaguchi class, open to members of the Okinawa Assn. of America, for more than a decade. Between the two sessions, he has about 40 students.


"The performing arts are very popular. Young people are taking Okinawan dance, learning folk songs, the sanshin, but they don't know the language of the songs," said Higa, 72. "We're trying to educate those born here, so they can carry on Okinawan culture."


::


Uchinaaguchi is believed to have split from Japanese between the 2nd and 8th centuries. It contains archaic traits, such as the consonant "p," that no longer exist in modern Japanese. The long "o" in Japanese is a long "u" in Uchinaaguchi, and the letter "e" often becomes "i."


Some words are similar. Sensei — teacher in Japanese — is shinshii in Uchinaaguchi.


But arigato — thank you — is nifee-deebiru. The word for "goodbye" in Japanese, sayonara, is guburii-sabira in Okinawan.


There are almost as many variants of the Okinawan language as there are islands in the Okinawan chain. Some are nearly as different from one another as they are from Japanese. UNESCO's list of endangered languages includes five from Japan's southernmost islands — Kunigami, Miyako, Yaeyama and Yonaguni in addition to Uchinaaguchi.


Shoichi Iwasaki, an applied linguistics professor at UCLA, is studying Ikema, spoken on the Miyako islands in southern Okinawa. He and several colleagues are compiling a dictionary, even as they realize that the language is unlikely to survive.


Uchinaaguchi, on the other hand, has a chance. It is the language of the main Okinawan island. If nothing else, it will live on in the lyrics of popular songs, much as Cajun French does through Louisiana-born musicians like Wayne Toups and Michael Doucet.





Read More..

The Lede: Reeva Steenkamp, Steve Biko and the Quest for Justice in South Africa

LONDON – The title of the presiding judge 35 years ago was the same, chief magistrate of Pretoria, and the venue for the hearing, a converted synagogue, was not far from the modern courthouse seen on television screens around the world in recent days as Oscar Pistorius, the gold medal-winning Paralympic athlete, fought for bail in the killing of his girlfriend, Reeva Steenkamp.

The case that unfolded in the last weeks of 1977, like the one featuring Mr. Pistorius, centered on a death that captured global attention. Then, too, it was the role of the chief magistrate, a jurist of relatively minor standing in South Africa’s legal system, to weigh whether it was a case of murder or mishap. Then, too, there were constituencies, inside the courtroom and beyond, that clamored passionately for their version of the truth.

The similarities – and dissimilarities – will have pressed in on anyone who was present in the Pretoria courtroom those decades ago, when the proceeding involved was an inquest, and the death that of Steve Biko, a 30-year-old black activist who was a popular youth leader of the anti-apartheid movement. By the miserable manner of his dying, alone, naked, and comatose on the floor of a freezing prison cell, Mr. Biko became, in death still more than in life, a powerful force for an end to South Africa’s institutionalized system of racial repression.

A British television report from South Africa in 1977, eight days after Steve Biko, an anti-apartheid activist, was beaten to death in police custody.

The two cases, of course, will find widely different places on history’s ladder. Mr. Pistorius, awarded bail on Friday after a hearing that was sensational for what it revealed of his actions in shooting Ms. Steenkamp, and for the raw emotions the athlete displayed in the dock, became a global celebrity in recent years for his feats as the Blade Runner, a track star who overcame the disability of being born with no bones in his lower legs.

But for all that it has been a shock to the millions who have seen his running as a parable for triumph in adversity, Mr. Pistorius’s tragedy — and still more, Ms. Steenkamps’s — has been a personal one. Mr. Biko’s death was considered at the time, as it has been ever since, as a watershed in the history of apartheid, a grim milestone among many others along South Africa’s progress towards black majority rule, which many ranked as the most inspiriting event in the peacetime history of the 20th-century when it was finally achieved in 1994.

Still, for a reporter who covered the Biko inquest for the Times as the paper’s South Africa correspondent through the turbulent years of the 1970’s, there were strong resonances in the week’s televised proceedings in Pretoria. Among them was the sheer scale of the media coverage, and the display of how live-by-satellite broadcasting and the digitalization of the print press, with computers, cellphones and Twitter feeds, have globalized the news business.

Oscar Pistorius facing the media during his bail hearing this week in Pretoria.

For the Pistorius hearing, there was a frenzied, tented camp of television crews outside the court, a crush among reporters struggling to get into the hearing, and platoons of studio commentators eager to have their say.

The crush among reporters outside the bail hearing for Oscar Pistorius this week in Pretoria.

On each of the 13 days the Biko inquest was in session, I had no trouble finding myself a seat in the airy courtroom. I took my lunch quietly with members of the Biko family’s legal team, and loitered uneasily during adjournments in an outside passageway, eavesdropping on the policemen who were Mr. Biko’s captors in his final days as they fine-tuned the testimony they were to give in court.

In the Pistorius case, the police again emerged poorly, having, as it seemed, bungled aspects of the forensic investigation in ways that could complicate the prosecution’s case that Ms. Steenkamp’s death was a case of premeditated murder — and having assigned the case to an officer who turned out to be under investigation in a case of attempted murder himself. But nothing in that bungling could compare with the sheer wretchedness of the security police officers in the Biko case, who symbolized, in their brutal and callous treatment of a defenseless man, and in the jesting about it I heard in that courtroom passageway, just how far below human decency apartheid had descended.

There was, too, the extraordinary contrast in the deportment of the magistrates in their rulings in the two cases, and what that said about the different South Africas of then and now. Desmond Nair, presiding at the Pistorius hearing, took more than two hours to review the evidence in the killing of Ms. Steenkamp, swinging back and forth in a meandering — and often bewildering — fashion between the contending accounts of Ms. Steenkamp’s death offered by Mr. Pistorius’s legal counsel and those put forward by the police.

Marthinus J. Prins, the chief magistrate in the Biko inquest, took an abrupt three minutes to deliver his finding, a numbing, 120-word exculpation of the policemen and government doctors who ushered Mr. Biko to his death on the stone-flagged floor of the Pretoria Central Prison. “The court finds the available evidence does not prove the death was brought about by any act or omission involving any offense by any person,” Mr. Prins said, reading hurriedly from a prepared statement before leaving the courtroom and slipping away by a rear door.

In finding that nobody was to blame in the black leader’s death, the magistrate brushed aside testimony suggesting what the policemen and doctors involved acknowledged many years later to have been true, when they petitioned for amnesty under the Truth and Reconciliation Commission process that sought to heal the wounds of apartheid: that Mr. Biko had been beaten in police custody, suffering a severe brain injury that was left untreated until he died.

The utter lack of compassion, and of anything resembling justice, was expressed in the dull-eyed satisfaction of Mr. Prins when I caught up with him an hour or so after the verdict in his vast, dingy office a few blocks from the courtroom.

“To me, it was just another death,” he said, pulling off his spectacles and rubbing his eyes. “It was just a job, like any other.”

Mr. Prins, who rose to his position through the apartheid bureaucracy, without legal training, appeared at that moment, as he had throughout the inquest, to be disturbingly sincere, yet utterly blinded. Faithful servant of the apartheid system, he had given it the clean bill of health it demanded, and freed the police to continue treating black political detainees as they chose. Among the country’s rulers, the verdict was embraced as a triumphal vindication, while those who chose to see matters more clearly understood it to be a tolling of history’s bell.

Listening to Mr. Nair delivering his ruling in the Pistorius case, there will have been many, in South Africa and abroad, who will have found his monologue on Friday confusing, circular in its argument, and numbingly repetitive. As an exercise in jurisprudence, it was something less than a stellar advertisement for a South African legal system that, at its best, is a match for any in the world, as it was back in 1977.

Sydney Kentridge, lead counsel for the Biko family at the inquest, moved seamlessly to England in the years that followed, and became, by widespread reckoning among his peers, Britain’s most distinguished barrister, still practicing in London now, at 90.

In the 2011 Steve Biko Lecture at the University of Cape Town, Sydney Kentridge spoke about the inquest into his death in 1977.

A host of other South African expatriates who fled apartheid have made outstanding careers as lawyers and judges in Britain, the United States, and elsewhere in the English-speaking world, but many others stayed at home, and continue to serve a court system that has fared rather better, in recent years, than many other institutions in the new South African state.

But even if Mr. Nair, in granting Mr. Pistorius bail, seemed no match in the elegance of his argument for South Africa’s finest legal minds, he nonetheless did South Africa proud. In the chaotic manner of his ruling, which sounded at times like a man grabbing for law books off a shelf, he was, indisputably, doing something that Mr. Prins, all those years before, had not even attempted: looking for ways to steer his course to justice. People will disagree whether Mr. Pistorius deserved the break he got in walking free from that courtroom, but nobody could reasonably contest that what we saw in his case was the working of a legal system that strives for justice, and not to rubber-stamp the imperatives of the state.

This post was revised to make it clear that Sydney Kentridge, the lawyer who represented Steve Biko’s family in 1977 and practiced law well into his 80s, is now 90.

Read More..

It's a Girl for The Price Is Right's Rachel Reynolds




Celebrity Baby Blog





02/23/2013 at 04:00 PM ET



On Feb. 13, the date was definitely right for Rachel Reynolds.


The Price Is Right model and husband David Dellucci welcomed their first child, daughter Ruby Rey Dellucci, on Wednesday, Feb. 13 — the couple’s third wedding anniversary.


Born at 10:54 p.m. in Baton Rouge, La., Ruby weighed in at 7 lbs., 5 oz. and was 20¼ inches long.


“David and I never dreamed that exactly three years from the day of our wedding we would welcome our little baby girl. We couldn’t have asked for a better anniversary gift,” Reynolds, 30, tells PEOPLE exclusively. “It’s very special! We are so in love with her and having so much fun. Every day is new and full of firsts for us and for Ruby.”


She and Dellucci, a former major league baseball player and member of the 2001 World Series Champion Arizona Diamondbacks, announced the pregnancy in August.


Rachel Reynolds Welcomes Daughter Ruby Rey
Courtesy Rachel Reynolds


– Sarah Michaud


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Digital billboard company issues $100-million threat against L.A.









An outdoor advertising company fighting to preserve dozens of digital billboards across Los Angeles warned this week that it would seek "substantially" more than $100 million from City Hall if it is ordered to remove any electronic signs targeted in a recent court ruling.


In an 11-page letter sent Friday, Clear Channel Outdoor told Mayor Antonio Villaraigosa, City Atty. Carmen Trutanich and Council President Herb Wesson that its digital signs are "valuable assets that the city cannot attempt to take away without paying just compensation."


The letter comes two months after a three-judge panel struck down a 2006 legal settlement approved by the City Council allowing Clear Channel and CBS Outdoor to convert 840 existing billboards to digital formats. The company installed 79 digital signs before the settlement was blocked.








The 2nd District Court of Appeal ordered a lower court to invalidate all digital conversions permitted under the agreement. But Sara Lee Keller, Clear Channel's lawyer, warned that if the council instructs the company to turn off the signs, "it would be exposed to liability to Clear Channel for the fair market value of such signs, which substantially exceeds $100 million."


"While litigating these claims would be costly and time-consuming for all … we believe it is important to be clear about the consequences," wrote Keller, who contends that other factors make all of the company's signs legal.


The letter drew a sharp response from Summit Media, a competing sign company that successfully sued to block the 2006 agreement. Phil Recht, the company's attorney, said Clear Channel has "no regard for the rule of law."


"Clear Channel is trying to bully the city into submission so that they can continue to make hundreds of millions of dollars in illegal profits from these digital billboards two courts ruled to be illegal," he said.


Clear Channel sent its letter one day before neighborhood activists and outdoor-advertising lobbyists — including the company and its representatives — took part in a working group to discuss possible digital sign legislation. One proposal up for discussion would allow new digital billboards to be installed in exchange for removing a greater number of static billboards.


Summit promised to work with neighborhoods on digital sign issues, saying the technology diminishes quality of life. In recent years, it has described the original 2006 agreement as a "sweetheart deal" that gave CBS and Clear Channel hundreds of millions of dollars in revenue.


Since the ruling, Clear Channel has been waging a publicity campaign in favor of digital billboards, putting together an advocacy group to argue on its behalf and touting support for its signs from such groups as AIDS Project Los Angeles, Art Share L.A. and the Los Angeles Area Chamber of Commerce. Those groups, among others, have asked the state Supreme Court to take another look at the ruling that invalidated the 2006 digital sign pact, according to Clear Channel's letter.


Clear Channel and a handful of other billboard companies also have been contributing tens of thousands of dollars in recent weeks to Proposition A, which is on the March 5 ballot and would raise the sales tax rate to 9.5% from 9%. That measure, if passed, is expected to generate more than $200 million annually for the city budget.


Meanwhile, Lamar Advertising, which has proposed its own plan for converting signs to digital formats, has been spending $5,000 per candidate on outdoor advertising promoting the City Council campaigns of Councilman Joe Buscaino and Assemblymen Bob Blumenfield (D-Woodland Hills), Felipe Fuentes (D-Sylmar) and Gil Cedillo (D-Los Angeles) as well as the city controller campaign of Councilman Dennis Zine.


Friday's letter from Clear Channel was accompanied by a legal claim, a document submitted before the filing of a lawsuit. Clear Channel spokesman Jim Cullinan said his company sent it because it must provide 90 days' notice before filing an action in court.


"This letter gives notice, but we hope it doesn't come to litigation," he said.


david.zahniser@latimes.com





Read More..

At War Blog: A Modern Medal Is Met with Modern Protest

It is only fitting that the announcement of a medal created for the digital age spawned its own Internet memes. As soon as Defense Secretary Leon E. Panetta announced the creation of the new Distinguished Warfare medal — immediately dubbed the Drone Medal — images such as the one below began appearing on blog after blog; in tweet after retweet.

The medal, Mr. Panetta explained, is intended to provide “recognition for the extraordinary achievements that directly impact on combat operations, but that do not involve acts of valor or physical risk that combat entails,” such as those piloting Predator or Reaper drones from a remote trailer. The medal has sparked much Photoshopped humor and heated online debate, much of it focusing on the Pentagon’s decision to rank it above the Purple Heart and the Bronze Star, both given to troops in combat.

As the Distinguished Warfare medal heads toward production, more than 13,000 people have signed an online petition demanding that the status of the medal be revised.

“Bronze Stars are commonly awarded with a Valor device in recognition of a soldier’s service in the heat of combat while on the ground in the theater of operation,” the petition states. “Under no circumstance should a medal that is designed to honor a pilot, that is controlling a drone via remote control, thousands of miles away from the theater of operation, rank above a medal that involves a soldier being in the line of fire on the ground.”

This was a sentiment echoed by many on Twitter:

Similar commentary could be found in opinion pieces on news sites, such as The Business Insider, which called it “The Most Ridiculous Thing The Pentagon Could Do” and in longer anecdotes of protest on the comments section of the United States Air Force announcement:

2/21/2013 12:28:33 AM ET
I don’t like this at all my father was in ground combat from 1944 to 1945 in France Germany and Czechoslovakia his highest medal was the bronze star I have a copy of the award hanging in my living room I can’t even imagine what he went through. Now some guy sitting in an air conditioned building in Nevada is going to get a medal rated higher than the bronze star and the purple heart. I don’t care how many terrorists he killed or how many hours he sat in front of that screen how motivated he is or how well he does his job it is inconcievable to me that he or she can possibly earn a medal rated this high. Giving them a medal is ok but lets not degrade the honor of others who have risked their lives and in some cases actually been wounded in combat serving our country.
Michael Sharkey, Trier Germany

According to the Defense Department, there is no controversy about the medal among military leaders. Each branch is in the process of drawing up their own specific guidelines and within two for four months, the first Distinguished Warfare Medals will be awarded.

“This is not a medal that will be awarded with the frequency of these other ones,”  Lt. Cmdr. Nate Christensen, a Defense Department spokesman, told At War, when asked why the medal should be above the Bronze Star.

Although there were some forms of recognition for drone operators and cyber operators before, none recognized truly exceptional acts of service, he said.

“This medal is visionary because it fills a void that existed before,” he said.

Although few people other than Pentagon officials came to the defense of the medal, some did circulate a piece by Maj. David Blair in the Air and Space Power Journal outlining the case for medals for drone operators.

For instance, consider a scenario in which Predator crews track a critical high­ value target to a safe house where he is then kinetically struck by a dynami­cally retasked F­16. In this case, both platforms’ crews perform their du­ties with excellence and professionalism. Perhaps that excellence merits decorations, or perhaps “doing your job” shouldn’t merit decoration. Ei­ther way, giving the F­16 pilot an award for heroism while excluding the Predator crews from consideration for the same sends a very clear message about what the institution believes is worth recognizing. This message ripples back into commissioning sources and light ­training pipelines, perpetuating perceptions and relative performance discrepan­cies through selection bias.

Published in July 2012, months before the announcement of the news medal, Major Blair’s piece did not address the flip-side: What happens when a member of the Predator crew receives a medal deemed more prestigious than the one awarded to the the F-16 pilot?

Read More..

Courtney Lopez: Gia Thinks Our Dog Is Having a Baby




Celebrity Baby Blog





02/22/2013 at 01:00 PM ET



Courtney Lopez: Gia Thinks Dog Having Baby
Denise Truscello/Wireimage


Mario Lopez is a man of his word.


Following a December wedding, the EXTRA host declared he and wife Courtney would get to work expanding their family immediately — and he wasn’t kidding.


In January, the couple discovered they were indeed expecting.


“Mario and I are so excited to add to our family! I found out a month ago and surprised Mario with the good news at breakfast,” Courtney tells PEOPLE.


But the proud parents aren’t the only ones gearing up for a new addition. Big sister Gia Francesca, 2, already has babies on the brain.


“Gia kind of understands that there is a baby in my belly,” Courtney notes. “She also told me our dog Julio has a baby in his belly — so who knows!”

Despite a bumpy start — “I had a rough couple of weeks when I first found out,” she shares — the mom-to-be is feeling better and already sporting quite the blossoming belly. “I am showing so much faster this time around,” she says.


And with warmer weather on the way, Courtney will be swathing her bump in floor-length frocks — but plans on foregoing a few fashion ensembles from her past.


“I love being pregnant in the summer! I live in maxi dresses,” she says. “Looking back at my first pregnancy, there are certain things that I wore and I have no idea why. I looked horrible and I won’t do that again!”


Originally from Pittsburgh, the expectant mama is thrilled to have settled down with her growing family on the West Coast. Her only wish? That her children will one day enjoy a winter wonderland.


“I don’t miss the East Coast at all — especially the humidity,” she explains. “The one thing I do want my children to experience from an early age is snow. There is nothing like being a kid playing in the snow.”


– Anya Leon


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Councilman's preferred successor holds edge in Westside district









When Los Angeles City Councilman Bill Rosendahl decided in October to retire and focus on battling cancer, he anointed Mike Bonin, his longtime chief of staff, as his preferred successor.


The March 5 primary election now seems Bonin's to lose.


Of four candidates seeking to represent Council District 11 — which includes Brentwood, Mar Vista, Venice and Westchester — Bonin has raised the most money ($380,000, including matching funds, more than four times the amount amassed by his nearest rival). The self-avowed "progressive activist" has also received hundreds of endorsements from politicians, business and labor leaders, environmental groups and residents.








"He's smart, he's a doer, and he's solution-oriented," said Austin Beutner, a conservative businessman and former mayoral hopeful who recently held a meet-and-greet event for Bonin in Pacific Palisades. "He's not an ideologue."


Bonin's three opponents — Frederick Sutton, 28, a part-time bartender and community activist; Tina Hess, 52, a prosecutor with the city attorney's office; and Odysseus Bostick, 36, a Westchester teacher and parent — all acknowledge the financial leader's sizable edge. But they say they're fed up with pothole-riddled streets, homeless encampments and out-of-control municipal expenditures. Bonin, they say, represents a politics-as-usual bureaucracy that has turned the City Council into what Sutton calls "a merry-go-round of lifetime politicians."


Having received $87,000 in donations and matching funds, Sutton sees his immediate goal as keeping Bonin from getting the simple majority of votes needed to seal victory in March. "Once you get into a runoff," Sutton said, "suddenly everything changes."


On the stump, Bonin, who will turn 46 next month, sounds savvy and confident. He has unveiled plans to make Los Angeles more employer-friendly (extend the Internet tax exemption for Silicon Beach companies, support tax credits and reduce red tape for film operations) and to improve residents' access to City Hall through regular community meetings and technology ("Hikes with Mike" and "Mayberry meets the iPhone")


After receiving his bachelor's degree in U.S. history at Harvard University, Bonin worked as a newspaper reporter before entering politics. The Massachusetts native moved to the Los Angeles area in the early 1990s. He lives in Mar Vista with his partner, Sean Arian, a consultant.


A Gold's Gym regular who eats mostly raw foods, Bonin sports five tattoos, including a recycling symbol on his left shoulder that serves partly "as a symbol of getting sober and taking a life that had been trash and making it productive again." After long overdoing it on drugs and alcohol, Bonin said, he has been sober for 18 years.


The diverse Westside sector he seeks to represent is rife with vocal activists and hot-button issues: congestion, transit construction, an imbalance between jobs and housing, transients and the modernization of Los Angeles International Airport. Like Rosendahl, Bonin opposes separating the northern runways but is all for updating the airport.


Bonin said his 17 years in public service have prepared him.


He first worked in city government as legislative deputy, district director and deputy chief of staff for former Councilwoman Ruth Galanter. He then became deputy chief of staff and district director for Rep. Jane Harman, who represented many 11th district neighborhoods before retiring from Congress. He has been Rosendahl's chief deputy since 2005.


Elected in 2005 and 2009, Rosendahl, 67, was favored to win a third and final term before being diagnosed with advanced cancer last summer.


Bonin said he has been inspired by his boss' spirit and resilience after months of grueling cancer treatments. "He's got the level of energy back that most of the staff finds exhausting to be around," Bonin told a group of elderly residents one recent afternoon.


Marcia Hanscom, a wetlands activist, said she endorsed Bonin after hearing his ideas for bringing government closer to the people and promoting nature in the city.


"He's got good values and instincts, and he also knows the inner workings of City Hall and its bureaucracy," she said in an email. "If he does as he says — getting and staying close to the constituents — he will not be so captured by City Hall as some think he is."


martha.groves@latimes.com


Times researcher Maloy Moore contributed to this report.





Read More..